NICE has published a costing template to accompany its guidance issued in October 2011 on the use of ticagrelor in acute coronary syndromes (ACS). The costing template can be used by health communities to assess the local impact of implementing the guidance, based on the local population.

The template does not provide estimates of future practice and therefore an overall cost impact figure is not available. Organisations should insert local assumptions in the template to reflect local circumstances to obtain the impact of implementing this guidance for them locally.